This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Fluticasone furoate, umeclidinium and vilanterol inhalation


Inhalation powder containing fluticasone furoate, umeclidinium bromide and vilanterol (as trifenatate).

Drugs List

  • fluticasone furoate 92microgram and umeclidinium 55microgram and vilanterol 22microgram inhalation powder
  • TRELEGY ELLIPTA 92microgram+55microgram+22microgram inhalation powder
  • Therapeutic Indications


    Chronic obstructive pulmonary disease

    Moderate to severe chronic obstructive pulmonary disease (COPD) in patients who are not adequately treated by a combination of an inhaled corticosteriod and a long acting beta2-agonist or a combination of a long acting beta2-agonist and long acting muscarinic antagonist.



    One inhalation once daily, at the same time of the day.

    Additional Dosage Information

    If dose is missed, take the next dose at the usual time the following day.


    Children under 18 years

    Precautions and Warnings

    Chronic infection
    Uncontrolled systemic infection
    Benign prostatic hyperplasia
    Diabetes mellitus
    Epileptic disorder
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Moderate hepatic impairment
    Narrow angle glaucoma
    Pulmonary tuberculosis
    Recent history of pneumonia
    Severe cardiovascular disorder
    Unstable cardiac disorder
    Urinary retention

    Advise visual disturbances may affect ability to drive or operate machinery
    Ensure patient has a fast acting bronchodilator available
    Contains lactose
    Check patient is using correct inhaler technique
    If visual disturbances occur, perform ophthalmic evaluation
    Monitor blood glucose closely in patients with diabetes mellitus
    Monitor for signs/symptoms of pneumonia in patients at risk
    May reduce serum potassium levels
    Systemic effects possible with any inhaled corticosteroid
    Do not withdraw this drug suddenly
    Discontinue if paradoxical bronchospasm occurs
    Discontinue if symptoms of acute angle closure glaucoma occur
    Advise patient not to use for relief of acute attacks
    Advise patient to rinse mouth with water after each dose
    Advise patient to seek medical advice if treatment is ineffective
    Consider issuing Steroid Treatment/Steroid Emergency Card
    High dose:Advise patient to avoid chickenpox,measles etc; see Dr if exposed
    Use regularly to maintain freedom from symptoms

    Pregnancy and Lactation


    Use the combination of fluticasone furoate, umeclidinium and vilanterol with caution during pregnancy.

    The manufacturer recommends this medication is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies show reproductive toxicity, however exposures were not clinically relevant. There is little data available on the use of fluticasone furoate, umeclidinium and vilanterol in pregnant women. A potential risk cannot be ruled out.


    The combination of fluticasone furoate, umeclidinium and vilanterol is contraindicated during breastfeeding.

    The manufacturer notes a decision should be made whether to cease breastfeeding or stop taking the medication. It is unknown whether fluticasone furoate, umeclidinium, vilanterol and their metabolites are excreted in human milk. Other corticosteroids, muscarinic antagonists and beta2-adrenergic agonists are detected in human milk, hence a risk to the infants cannot be excluded.

    Side Effects

    Atrial fibrillation
    Back pain
    Blurred vision
    Candidiasis (mouth or throat)
    Dry mouth
    Hypersensitivity reactions
    Oropharyngeal pain
    Respiratory tract infection
    Supraventricular tachycardia
    Upper respiratory tract infection
    Urinary tract infections

    Further Information

    Last Full Review Date: February 2021

    Reference Sources

    Summary of Product Characteristics: Trelegy Ellipta 92micrograms/55micrograms/22micrograms inhalation powder. GlaxoSmithKline UK. Revised September 2020.

    NICE Evidence Services Available at: Last accessed: 02 February 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.